跳转至内容
Merck
所有图片(1)

Key Documents

View All Documentation

L109

Sigma-Aldrich

Lorglumide sodium salt

solid

别名:

(±)-4-[(3,4-Dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxopentanoic acid sodium salt, CR 1409

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C22H31Cl2N2NaO4
CAS号:
1021868-76-7
分子量:
481.39
MDL號碼:
MFCD00083183
分類程式碼代碼:
12352200
PubChem物質ID:
24278098
NACRES:
NA.32

形狀

solid

顏色

white

溶解度

45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: >10 mg/mL
H2O: 10 mg/mL
methanol: 28 mg/mL

SMILES 字串

[Na+].CCCCCN(CCCCC)C(=O)C(CCC([O-])=O)NC(=O)c1ccc(Cl)c(Cl)c1

InChI

1S/C22H32Cl2N2O4.Na/c1-3-5-7-13-26(14-8-6-4-2)22(30)19(11-12-20(27)28)25-21(29)16-9-10-17(23)18(24)15-16;/h9-10,15,19H,3-8,11-14H2,1-2H3,(H,25,29)(H,27,28);/q;+1/p-1

InChI 密鑰

JCNPYMDDOUQTBK-UHFFFAOYSA-M

基因資訊

human ... CCKAR(886)

應用

Lorglumide sodium salt has been used as a cck-a (cholecystokinin A) receptor antagonist for peptide determination in rat islet cells. It has been used as a CCK1 inhibitor to check the effect of cck1 (cck-a) and cck2 (cck-b) receptors on cerulein-induced upregulation of egr-1 (early growth response 1) expression in rat pancreatic acinar cells.

生化／生理作用

Potent and selective non-peptide cholecystokinin (CCKA) receptor antagonist; orally active.

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 2

閃點（°F）

Not applicable

閃點（°C）

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

F Makovec et al.
Arzneimittel-Forschung, 37(11), 1265-1268 (1987-11-01)
Derivatives of 5-(dipentylamino)-5-oxo-pentanoic acid are a new class of non-peptide cholecystokinin (CCK) antagonists. The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide, CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent CCK
M D'Amato et al.
British journal of pharmacology, 102(2), 391-395 (1991-02-01)
1. Three recently described non-peptide cholecystokinin (CCK) antagonists (devazepide, lorglumide, loxiglumide) have been studied for their antagonism of the contraction to cholecystokinin-octapeptide (CCK-OP) in human alimentary muscle and guinea-pig intestine. 2. Each antagonist caused a concentration-dependent inhibition of the contraction
Yukio Ikeda et al.
Biochemical and biophysical research communications, 333(3), 778-786 (2005-06-22)
The glucose-induced insulin secretion is fine-tuned by numerous factors. To systematically identify insulinotropic factors, we optimized a primary beta-cell-based functional assay to monitor intracellular Ca2+ flux ([Ca2+]i). By this assay system, we successfully identified several insulinotropic peptides including cholecystokinin, gastrin
H W Suh et al.
Peptides, 16(7), 1229-1234 (1995-01-01)
Various doses of sulfated cholecystokinin octapeptide (CCK-8s) injected intracerebroventricularly (ICV) alone did not show any antinociceptive effect. CCK-8s (0.01-1 ng) pretreated ICV for 10 min dose-dependently attenuated the inhibition of the tail flick response induced by ICV-administered morphine (2 micrograms).
G L Edwards et al.
Annals of the New York Academy of Sciences, 897, 192-197 (2000-02-17)
Ingestion of food and fluid stimulates release of a number of peptides from the gastrointestinal system. These peptides are recognized to act as neurotransmitters/neuromodulators and act at both peripheral and central receptors. Many studies indicate that these peptides are important
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门